Format
Sort by
Items per page

Send to

Choose Destination

Best matches for drug-eluting stents AND economics AND percutaneous coronary intervention AND restenosis:

Search results

Items: 1 to 20 of 102

1.

Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis.

Poder TG, Erraji J, Coulibaly LP, Koffi K.

PLoS One. 2017 May 12;12(5):e0177476. doi: 10.1371/journal.pone.0177476. eCollection 2017. Review.

2.

Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.

Zbinden R, von Felten S, Wein B, Tueller D, Kurz DJ, Reho I, Galatius S, Alber H, Conen D, Pfisterer M, Kaiser C, Eberli FR.

Cardiovasc Ther. 2017 Feb;35(1):19-25. doi: 10.1111/1755-5922.12229.

PMID:
27662632
3.

The NICE recommendation for drug-coated balloons and its global impact.

Eccleshall S, Waliszewski M.

Ther Adv Cardiovasc Dis. 2015 Jun;9(3):87-94. doi: 10.1177/1753944715574655. Epub 2015 Mar 2. Review.

PMID:
25731186
4.

Understanding the economic impact of intravascular ultrasound (IVUS).

Alberti A, Giudice P, Gelera A, Stefanini L, Priest V, Simmonds M, Lee C, Wasserman M.

Eur J Health Econ. 2016 Mar;17(2):185-93. doi: 10.1007/s10198-015-0670-4. Epub 2015 Feb 11.

PMID:
25669755
5.

Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis.

Chang TI, Montez-Rath ME, Shen JI, Solomon MD, Chertow GM, Winkelmayer WC.

J Am Heart Assoc. 2014 Oct 21;3(5):e001356. doi: 10.1161/JAHA.114.001356. Erratum in: J Am Heart Assoc. 2015 Apr;4(4). pii: e000634. doi: 10.1161/JAHA.115.000634.

6.

Drug-eluting versus bare-metal coronary stents: where are we now?

Amoroso NS, Bangalore S.

J Comp Eff Res. 2012 Nov;1(6):501-8. doi: 10.2217/cer.12.64. Review.

PMID:
24236469
7.

[SICI-GISE position paper on drug-coated balloon use in the coronary district].

Cortese B, Sgueglia GA, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A; Italian Society of Interventional Cardiology (SICI-GISE).

G Ital Cardiol (Rome). 2013 Oct;14(10):681-9. doi: 10.1714/1335.14836. Italian.

PMID:
24121894
8.

Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry.

Kutcher MA, Brennan JM, Rao SV, Dai D, Anstrom KJ, Mustafa N, Sedrakyan A, Booth ME, Douglas PS, Messenger JC.

Catheter Cardiovasc Interv. 2014 Feb;83(2):171-81. doi: 10.1002/ccd.25108. Epub 2013 Aug 31. Erratum in: Catheter Cardiovasc Interv. 2014 Jul 1;84(1):168. Sedrakayan, Art [corrected to Sedrakyan].

PMID:
23907981
9.

Medical therapy v. PCI in stable coronary artery disease: a cost-effectiveness analysis.

Wijeysundera HC, Tomlinson G, Ko DT, Dzavik V, Krahn MD.

Med Decis Making. 2013 Oct;33(7):891-905. doi: 10.1177/0272989X13497262. Epub 2013 Jul 25.

PMID:
23886676
10.

Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis.

Dorenkamp M, Boldt J, Leber AW, Sohns C, Roser M, Boldt LH, Haverkamp W, Bonaventura K.

Clin Cardiol. 2013 Jul;36(7):407-13. doi: 10.1002/clc.22130. Epub 2013 Apr 17.

11.

Evaluation of a policy of selective drug-eluting stent implantation for patients at high risk of restenosis.

Shugman IM, Idris H, Kadappu KK, Nguyen P, Taylor D, Rajaratnam R, Leung D, Hopkins AP, Lo S, Juergens CP, French JK.

Heart Lung Circ. 2013 Jul;22(7):523-32. doi: 10.1016/j.hlc.2012.12.011. Epub 2013 Feb 28.

PMID:
23454032
12.

Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice.

Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW.

Arch Intern Med. 2012 Aug 13;172(15):1145-52. doi: 10.1001/archinternmed.2012.3093.

PMID:
22777536
13.

Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).

Amin AP, Reynolds MR, Lei Y, Magnuson EA, Vilain K, Durtschi AJ, Simonton CA, Stone GW, Cohen DJ.

Am J Cardiol. 2012 Sep 15;110(6):765-70. doi: 10.1016/j.amjcard.2012.05.006. Epub 2012 May 30.

PMID:
22651880
14.

Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.

Bonaventura K, Leber AW, Sohns C, Roser M, Boldt LH, Kleber FX, Haverkamp W, Dorenkamp M.

Clin Res Cardiol. 2012 Jul;101(7):573-84. doi: 10.1007/s00392-012-0428-2. Epub 2012 Feb 21.

PMID:
22350752
15.

Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.

Birim Ö, Bogers AJ, Kappetein AP.

J Cardiovasc Surg (Torino). 2012 Oct;53(5):641-50. Epub 2012 Jan 17. Review.

PMID:
22252542
16.

Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.

Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW; ORAR III Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8.

PMID:
22109997
17.

Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.

Yeh RW, Normand SL, Wolf RE, Jones PG, Ho KK, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin AP, Spertus JA.

Circulation. 2011 Oct 4;124(14):1557-64. doi: 10.1161/CIRCULATIONAHA.111.045229. Epub 2011 Sep 6.

18.

Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.

Venkitachalam L, Lei Y, Stolker JM, Mahoney EM, Amin AP, Lindsey JB, Kennedy KF, Pencina MJ, Lopez JJ, Kleiman NS, Cohen DJ; EVENT Registry Investigators.

Circulation. 2011 Aug 30;124(9):1028-37. doi: 10.1161/CIRCULATIONAHA.110.978593. Epub 2011 Aug 15.

19.

Cost analysis of four major drug-eluting stents in diabetic populations.

Saadi R, Cohen S, Banko D, Thompson M, Duong M, Ferko N.

EuroIntervention. 2011 Jul;7(3):332-9. doi: 10.4244/EIJV7I3A57.

20.

Cost-effectiveness of drug-eluting stents in patients with stable coronary artery disease.

Hung CS, Cheng CL, Chao CL, Kao HL, Chen MF, Lin NP.

J Formos Med Assoc. 2011 Feb;110(2):109-14. doi: 10.1016/S0929-6646(11)60017-X.

Supplemental Content

Loading ...
Support Center